Injectable Feedstock Surfaces and Endotoxin Control Boundaries

The injectable conversion of the Yuxingcao Qinlan Oral Solution Veterinary Grade API is constrained by the interaction between residual endotoxin, thermolabile flavonoids, and divalent cations present in source water. A working parenteral batch is prepared from the dried extract fraction rather than the preserved oral solution base, because benzaldehyde-derived aromatic compounds in the Houttuynia cordata essential oil can exceed the preservative-free threshold for parenteral administration. The extract is dissolved in Water for Injection at 40°C to 50°C in a jacketed vessel with a bottom-mounted magnetic impeller operated at 120 rpm to avoid vortex entrainment. The ratio is fixed at 15% w/v dry extract equivalent, corresponding to 150 g of API per 1.0 L of final dilution. After cooling to 20°C to 25°C, pH is adjusted to 5.8 to 6.2 with 0.1 M citrate buffer. Dissolved oxygen is maintained below 0.5 mg/L by nitrogen sparging through a 0.22 µm hydrophobic filter before and after pH adjustment.

Bacterial endotoxin reduction cannot rely solely on terminal filtration because the Houttuynia-derived polysaccharide fraction can load the retentate with endotoxin-bound micelles. A sequential clarification train is used: a 0.45 µm polyethersulfone depth filter followed by a 0.22 µm PVDF membrane filter, then a 10 kDa polysulfone ultrafiltration cassette operated at a transmembrane pressure of 0.7 bar to 1.2 bar. Before membrane filtration, 0.1% w/v acid-activated carbon is added for 30 minutes at 15°C to 20°C to reduce lipopolysaccharide burden; this step removes 5% to 12% of total flavonoid markers and must be recovery-validated by HPLC. The final filtrate is tested for sterility by USP 71, bacterial endotoxins by USP 85, and particulate matter by USP 788. The endotoxin acceptance criterion is calculated as K/M, where K is 5 EU/kg/h for intravenous administration and M is the maximum bolus dose in mg/kg/h. No antioxidant or bacteriostatic agent is added because the route of administration is assumed to be intravenous; the solution is filled as single-dose 10 mL amber type I glass vials under laminar flow Grade A.

Terminal sterilization at 121°C for 15 minutes is only permissible when a stability study demonstrates that volatile 2-undecanone loss remains below 10% and the indirubin peak area does not shift by more than 8%. Published data for the exact stability threshold of the Isatis-derived indigo alkaloids under saturated steam is limited; each incoming API lot must therefore be evaluated by a pilot autoclave cycle using an F0 value not exceeding 12 minutes for a 10 mL fill. If terminal sterilization fails the lot-specific acceptance criteria, the formulation is converted to aseptic filtration and filled through a 0.22 µm sterile filter under isolator conditions. The desired visual clarity target is protected from precipitation caused by calcium and magnesium traces; 0.01% w/v disodium edetate is incorporated when water hardness exceeds 200 ppm as CaCO3. The process is incompatible with polycarbonate filter housings because the essential oil fraction can extract bisphenol A at trace levels above the ICH Q3D extractable limit.

A compressed veterinary tablet containing the Yuxingcao Qinlan Oral Solution Veterinary Grade API cannot be developed as a direct-compression dry blend unless the API particle size is engineered to a D50 of 75 µm to 125 µm and the loss on drying is held at 3.0% to 4.0%. Above 4.5% moisture, the Houttuynia-derived polar flavonoids plasticise the microcrystalline cellulose interface and cause picking on the punch face; below 1.5% moisture, granule tensile strength drops and capping occurs at the pre-compression roll. A representative 500 mg tablet core is formulated with 150 mg of spray-dried API, 180 mg of microcrystalline cellulose PH102, 85 mg of lactose monohydrate, 30 mg of crospovidone, 5 mg of colloidal silicon dioxide and 5 mg of magnesium stearate. This yields a 30% w/w extract loading, which is close to the upper practical limit for disintegration and friability control. The raw blend is granulated in a high-shear mixer at an impeller speed of 300 rpm and a chopper speed of 1,500 rpm using a 30:70 ethanol-water binder at 12% w/w addition until the wet mass reaches a torque rise of 35 N·m above baseline.

The wet granules are discharged through a 2.0 mm stainless steel sieve and dried in a fluid-bed dryer at an inlet air temperature of 60°C to 65°C until moisture reaches 2.5% to 3.5%. Drying time normally ranges from 25 minutes to 40 minutes, depending on ethanol removal efficiency in the explosion-proof dryer duct. The dried granules are passed through an oscillating granulator fitted with a 0.8 mm mesh and blended with the disintegrant and lubricant in a V-blender for 15 minutes at 25 rpm. Compression is performed on a 16-station rotary tablet press with 12 mm flat-faced bevel-edge punches, a forced feeder speed of 20 rpm, and a main compression force between 6 kN and 10 kN. Tablet hardness is held at 5 kp to 8 kp, friability is below 0.8%, and disintegration is below 15 minutes by USP 701 in water at 37°C. The dissolution acceptance criterion for release follows USP 711 apparatus 2 at 50 rpm with 900 mL of pH 6.8 phosphate buffer; Q is not less than 75% at 45 minutes. The finished oral tablet is packaged in PVC/aluminum blisters with a desiccant pouch when the distribution climate exceeds 60% relative humidity. Alkaline fillers such as sodium bicarbonate must be avoided because the isolated flavonoid fraction degrades rapidly above pH 7.5.

Storage stability for this tablet form is dominated by migration kinetics of residual volatile oil from the API into the film coating. If a film coating is applied, a 2% w/w hydroxypropyl methylcellulose barrier coat is applied before a pigmented seal coat to limit 2-undecanone migration into the primary blister. The final tablet is a bolus-type oral dosage for pigs from 25 kg body weight upward; for smaller species the same granule is filled into capsules rather than compressed into full-size tablets. Batch records document moisture, granule size distribution, and content uniformity because the herbal extract contains multiple markers that are not evenly distributed across the dried matrix. Content uniformity follows USP 905, with acceptance value not greater than 15.0 for an assayed marker expressed as rutin equivalent.

What Limits Capsule Plug Formation Above 25% Dry Extract Loading?

Capsule filling stations fitted with dosator nozzles exhibit cohesive arching when the spray-dried API content exceeds 25% by weight in a free-flowing fill. The phenolic acid-enriched fraction has a glass transition temperature close to 45°C, and frictional heat from the tamping pins can raise the powder temperature to 38°C during long filling runs, causing plasticization and plug formation. To maintain dosator-controlled fill weight within ±3%, the dry extract is first mixed with 30% w/w lactose monohydrate, 20% w/w microcrystalline cellulose PH102, 1.5% w/w colloidal silicon dioxide, and 0.5% w/w magnesium stearate. The extract ratio is 25% w/w, producing a 400 mg fill weight for size 1 capsules. The pre-blend is screened twice through a 30-mesh sieve and blended in a bin blender for 10 minutes at 12 rpm. Flow is qualified before every fill run: Hausner ratio must be below 1.25, and Carr index must be below 20%. If the Hausner ratio rises above 1.30, the batch is rejected for capsule filling and re-granulated.

The capsule shell itself must be compatible with residual moisture from the dried extract. Gelatin shells become brittle when the shell moisture falls below 12% and tacky above 18%; therefore a two-piece hard gelatin capsule is selected only when the fill moisture is below 3.5% and the packaging headspace humidity is held at 45% to 55% RH. For high-humidity markets, hydroxypropyl methylcellulose capsules with a shell moisture of 3% to 8% are preferred because the shell does not crosslink with aldehydes from the essential oil. Disintegration of the filled capsule is assessed by USP 701; no capsule is retained above 15 minutes. The capsule fill is also tested for microbial limits by USP 62 and total aerobic microbial count by USP 61 because botanicals can carry a higher bioburden than synthetic APIs. The finished capsule is intended for companion animals and small ruminants where weight-based dosing is commonly calculated by body weight. Published field data for the exact plug formation threshold at continuous filling speeds above 60,000 capsules per hour is limited; process capability is therefore re-qualified whenever the filling speed is increased by more than 20%.

Premix homogeneity is controlled at the weigh hopper, not the ribbon mixer.

In medicated feed premix production, the Yuxingcao Qinlan Oral Solution Veterinary Grade API is transferred from the liquid concentrate to a dry carrier by a single-pass spray adsorption step. A 2% w/w use-rate premix is prepared by diluting 2 parts of the dried extract with 98 parts of a carrier blend consisting of 60% ground corncob, 30% calcium carbonate, and 10% precipitated silica. The liquid-to-solid ratio during spraying is 0.8:1.0, and the carrier bed temperature is maintained at 55°C to 60°C to prevent thermal degradation of volatile 2-undecanone. The resulting free-flowing premix is passed through a 60-mesh screen before blending. Homogeneity is generated in a horizontal ribbon mixer with a working capacity of 200 kg, a fill level of 60%, a ribbon tip speed of 1.2 m/s, and a mixing time of 15 minutes. Mixing time beyond 20 minutes is contraindicated because the fine silica fraction migrates to the bottom of the trough and creates a reverse segregation gradient.

The uniformity of the premix is verified with GB/T 5918 or an equivalent in-house marker method, using ten sampling points along the mixer trough. The coefficient of variation for the marker assay must be below 5.0% for initial release and below 7.0% for field transfer samples. The premix is then incorporated into complete feed at a dilution of 2 kg per 1,000 kg of feed to produce a final feed concentration of 40 mg/kg active premix. The terminal feed is produced in a vertical screw mixer for 10 minutes, and carryover is limited by sequencing the herbal premix after non-antibiotic feeds to avoid cross-contact with ionophore coccidiostats. Compliance is anchored to FDA 21 CFR 225 for medicated feed manufacturing and to EU Regulation 2019/4 for veterinary medicinal products in medicated feed. The finished premix is filled into 25 kg multi-wall paper sacks with an inner polyethylene liner, and each sack is tagged with the API lot number, mixing time, and moisture content.

Fluid-bed granulation of the API is selected under conditions where dusting from dry powder blending exceeds an operator exposure threshold of 0.3 mg/m³ for airborne botanical dust. A top-spray granulator with a 1.8 m² distributor plate is charged with 35% w/w spray-dried API, 25% w/w lactose monohydrate, 20% w/w mannitol, and 20% w/w pregelatinised starch. The binder is a 5% w/v povidone K30 solution in 50:50 ethanol-water, sprayed at an atomisation air pressure of 1.2 bar and a spray rate of 80 g/min. Inlet air temperature is set at 65°C, and product temperature is kept between 35°C and 40°C to avoid essential oil loss. The bed dew point is controlled at 5°C to 8°C, which prevents electrostatic clumping on the distribution plate. Granulation continues until the median granule size reaches 0.5 mm to 1.0 mm; the endpoint is determined by near-infrared moisture readings rather than time alone. Final moisture is dried to 3.0% or below.

The dried granules are screened through a 0.8 mm mesh, and fines below 150 µm are recycled at no more than 15% of the total batch weight to prevent over-granulation. The finished granule is filled into 100 g aluminum-lined pouches designed for oral top-dress or drench mixing. Friability of the granule core is below 1.0% after tumbling for 100 revolutions in a Roche friabilator. Disintegration in water at 37°C is checked by USP 701 and is normally below 5 minutes because mannitol channels provide rapid water penetration. The granule form is preferred for weaned piglets when direct feed intake may vary; the oral suspension prepared from the granule is dosed at 1 g per 20 kg body weight, but this dosage must be adjusted against the potency marker on the API certificate of analysis. Residual ethanol is controlled below 5,000 ppm by USP 467, and residual moisture below 4.0% by loss on drying. The end product is intentionally not film-coated because the coating would delay dissolution in drinking water applications.

When Rehydration Temperature Drives Soluble Powder Clarity

When the dried API is reconstituted into drinking water, the limiting factor is the water temperature at the farm, not the original powder blend. Source water for reconstitution is treated to potable water criteria under EU Directive 98/83/EC or WHO drinking-water quality guidelines. The Houttuynia essential oil fraction contains 2-undecanone and decanoyl acetaldehyde, which are poorly soluble in cold water and oxidize rapidly above 50°C. The soluble powder is therefore designed for reconstitution at 30°C to 35°C to hold turbidity below 20 NTU. A representative water-soluble powder is prepared by dry-adsorbing 10 parts of the extract onto 70 parts of glucose monohydrate, 15 parts of citric acid, and 5 parts of β-cyclodextrin. The β-cyclodextrin inclusion complex is formed in a high-shear rotor-stator mixer at 3,000 rpm for 20 minutes; this pre-masking step is necessary because the free essential oil causes foaming and visible surface droplets in the drinking line. The powder is filled into 500 g sachets and dissolved at 100 g per 200 L of drinking water to produce a 0.05% w/v extract solution.

The reconstituted solution is maintained at pH 6.0 to 6.8 with citric acid buffering; below pH 4.5 the indirubin-like alkaloids precipitate as a dark blue sediment, and above pH 8.0 the flavonoid fraction darkens within 4 hours. The drinking solution is not compatible with chlorinated water at free chlorine levels above 1.5 ppm unless 0.2% w/v sodium thiosulfate is added first, because chlorine oxidizes the decanoyl acetaldehyde marker. The solution is cleared of undissolved carrier by passage through a 200 µm in-line strainer before entering the nipple drinker line. After reconstitution the solution is held for no longer than 12 hours at ambient temperature, and ultraviolet exposure is minimized because the essential oil fraction forms photo-oxidation products. The end product is intended for mass administration to broilers, layers, and nursery pigs through proportioner medication systems; the final water solution is a clear amber liquid with a target turbidity below 20 NTU after 60 seconds of mixing.

A shelf-stable oral solution presentation requires preservative challenge testing and headspace oxygen control more than the powder forms. The final solution is prepared at 10% w/v dry extract equivalent in purified water with 0.1% w/v sodium benzoate and 0.05% w/v potassium sorbate as the preservative system. The pH is adjusted to 5.0 to 5.5 because the preservative activity of sodium benzoate falls above pH 6.0 and the extract remains stable in this range. Before preservative addition, the solution is sparged with nitrogen for 30 minutes through a 0.22 µm filter, and the headspace of the filling vessel is blanketed with nitrogen at an overpressure of 0.2 bar. The batch is mixed in a 316L vessel with a dished bottom and a low-shear impeller at 80 rpm to avoid foaming from saponins present in the botanical source. The solution is filtered through a 5 µm polypropylene cartridge to remove insoluble plant cell debris but is not filtered through 0.22 µm because this would remove colloidal polysaccharides and alter the marker profile.

Microbial challenge is performed by USP 51 using Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis; the acceptance criterion is a 3-log reduction at 14 days for bacteria and a 1-log reduction at 14 days for fungi, with no recovery at 28 days. The filled solution is packaged in 100 mL and 500 mL high-density polyethylene bottles with induction-sealed closures, and the fill volume has an overage of 2.0% to 3.0% to compensate for sorptive loss on the bottle wall. The product is stored below 30°C and protected from light; no terminal sterilization is applied, so the preservative system carries the full microbiological stability load. The oral solution form is suitable for direct dosing pumps in poultry houses and for small-scale pig feeding operations. The conversion from the API liquid concentrate to this finished solution is the shortest process route, but it requires the tightest microbiological control because the finished solution contains no growth-limiting carrier. If the incoming API lot carries a total aerobic microbial count above 1,000 CFU/g, it is pre-treated by heat shock at 80°C for 15 minutes before oral solution manufacture, provided the marker recovery remains within 95% to 105% of the certificate value.